B.Pharmacy and two years Diploma in Medical Imaging Technology from State Board of Technical Education Or Any equivalent recognized Board, University. Dr. Bhubaneswar Borooah Cancer Institute
National Institute of Immunology require Biotechnology or Life Science candidate. experience in basic molecular biology, cloning, expression, and purification of recombinant proteins
Post Graduate degree in Chemistry or Graduate, Post Graduate Degree in Professional Course selected through National Eligibility Tests – CSIR-UGC NET including lectureship Assistant Professorship or GATE.
Anusandhan National Research Foundation aims to establish convergence research Centres of Excellence to undertake cutting edge, innovative and impactful research at the interface of Science, Technology, Humanities, Social Sciences and Society.
Responsible for LC-MS, MS method development, method validation and batch analysis. Impurity profiling for identification of unknown impurities in small molecules.
Granules India is a vertically integrated, high-growth pharmaceutical company with 38 years of proven performance and increasing performance and increasing presence across the world.
PHARMACY GRADUATE WITH 3 TO 7 YEARS OF EXPERIENCE IN FORMULATION DEVELOPMENT OF STERILE DOSAGE FORMS AS PER GUIDELINES OF US, EU, CANADA, BRAZIL AND ROW MARKET.
Candidate should have experience in the IP evaluation of APIs, Infringement analysis, FTO analysis and summary reports, patent searching, patent drafting, patent filing and patent prosecution.
AbbVie and IGI Therapeutics SA, a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation, Inc. (IGI), today announced an exclusive licensing agreement for IGIs lead investigational asset, ISB 2001, developed using IGIs proprietary BEAT protein platform, for oncology and autoimmune diseases
Ascentage Pharma a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that its proprietary novel Bcl-2 selective inhibitor lisaftoclax (APG-2575) has been approved by China’s National Medical Products Administration (NMPA) for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who have previously received at least one systemic therapy including Bruton’s tyrosine kinase (BTK) inhibitors, which makes lisaftoclax the first Bcl-2 inhibitor receiving conditional approval
Milestone Pharmaceuticals Inc announced that the U.S. Food and Drug Administration (FDA) has accepted for review Milestone’s response to issues raised in the Complete Response Letter (CRL) for CARDAMYST™ (etripamil) nasal spray, an investigational, novel therapy for the treatment of patients with paroxysmal supraventricular tachycardia (PSVT). The FDA has assigned a new Prescription Drug User Fee Act (PDUFA) target action date of December 13, 2025.
A Direct Benefit Transfer (DBT) amount of Rs. 4000 for Diploma Apprentices will be provided by Govt. of India under NATS scheme. The above stipend is inclusive of DBT amount wherever applicable.